2-(4-ethylpiperazin-1-yl)-4-methyl-6-aminoquinoline | 710328-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-ethylpiperazin-1-yl)-4-methyl-6-aminoquinoline
• 英文别名: 2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-amine
• CAS: 710328-02-2
• 化学式: C₁₆H₂₂N₄
• 分子量: 270.377
• InChiKey: KCTWLQGNSLMOGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  45.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-ethylpiperazin-1-yl)-4-methyl-6-aminoquinoline 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N¹-(2-(diethylamino)ethyl)-N²-(2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6- yl)oxalamide
  参考文献：
  名称：

  [EN] QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE
  [FR] INHIBITEURS DE LA QUINOLÉINE DE RAD52 ET MÉTHODES D'UTILISATION

  摘要：

  本公开涉及到Formula I和Formula I的化合物及其药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于调节RAD51活性，并可用于治疗RAD51活性参与的疾病，如癌症。

  公开号：

  WO2021067604A1
• 作为产物：
  描述：

  6-硝基喹哌嗪丁二烯二酸 在 palladium on activated charcoal 、 氢气 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 为溶剂， 生成 2-(4-ethylpiperazin-1-yl)-4-methyl-6-aminoquinoline
  参考文献：
  名称：

  [EN] QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE
  [FR] INHIBITEURS DE LA QUINOLÉINE DE RAD52 ET MÉTHODES D'UTILISATION

  摘要：

  本公开涉及到Formula I和Formula I的化合物及其药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于调节RAD51活性，并可用于治疗RAD51活性参与的疾病，如癌症。

  公开号：

  WO2021067604A1

文献信息

• [EN] Inhibitors of RAD52 Recombination Protein and Methods Using Same<br/>[FR] INHIBITEURS DE LA PROTÉINE DE RECOMBINAISON RAD52 ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：UNIV DREXEL

  公开号：WO2016196955A1

  公开（公告）日：2016-12-08

  The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

  本发明包括用于预防或治疗患有癌症的受试者的新型RAD52抑制剂。本发明还包括一种预防或治疗患有癌症的受试者的方法，该方法包括向受试者投与本发明化合物的有效量。在某些实施方式中，受试者还会投与至少一种其他治疗药物。
• Quinoline compounds for use in mch receptor related disorders
  申请人：Frimurer Michael Thomas

  公开号：US20060111357A1

  公开（公告）日：2006-05-25

  The present invention relates to the use of quinoline compounds for the preparation of a pharmaceutical and/or a cosmetic composition for the treatment, prophylaxis and/or diagnosis of a condition caused by or involving a melanin-concentrating hormone. The invention also relates to novel quinoline compounds per se. The quinoline compounds have been found to interact with a melanin-concentrating hormone receptor, a MCH receptor. The compounds have modulating activity on the MCH receptor such as e.g. antagonistic, agonistic or allosteric activity and are useful for medicinal or cosmetic purposes such as, e.g. in the treatment or prevention of feeding disorders like obesity, metabolic syndrome, Type II diabetes, bulimia, etc. or in the treatment or prevention of depression.

  本发明涉及使用喹啉化合物制备用于治疗、预防和/或诊断由或涉及黑色素浓缩激素引起的疾病的药物和/或化妆品组合物。本发明还涉及新型喹啉化合物本身。已发现喹啉化合物与黑色素浓缩激素受体（MCH受体）相互作用。该化合物对MCH受体具有调节活性，例如拮抗、激动或异构活性，并可用于药用或化妆品用途，例如治疗或预防饮食障碍，如肥胖症、代谢综合征、2型糖尿病、贪食症等，或治疗或预防抑郁症。
• Inhibitors of RAD52 recombination protein and methods using same
  申请人：Mazin Alexander V.

  公开号：US10442817B2

  公开（公告）日：2019-10-15

  The present invention includes novel RAD52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

  本发明包括新型 RAD52 抑制剂，用于预防或治疗有需要的受试者的癌症。本发明还包括一种预防或治疗有需要的受试者癌症的方法，该方法包括向受试者施用有效量的本发明化合物。在某些实施方案中，受试者进一步施用至少一种额外的治疗剂。
• Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors
  作者：Fen Jiang、An-ping Guo、Jia-cheng Xu、Hui-Jie Wang、Xiao-fei Mo、Qi-Dong You、Xiao-Li Xu

  DOI：10.1016/j.ejmech.2017.07.080

  日期：2017.12

  In order to discover novel Hsp90 inhibitors targeting the C-terminal ATP binding pocket, a novobiocin derivative based ROCS model was constructed for virtual screening. Compound 13 was identified as the lead compound and then systematical structure activity relationship (SAR) study was conducted. These efforts led to compound 69, which exhibited potent anti-proliferative activities against MCF7 and SKBr3 breast cancer cell lines. In 4T1 mice breast cancer models, 69 exhibited potent tumor growth inhibition and anti-metastasis effect. Compound 69 as a potent antitumor agent targeting the Hsp90 C-terminal is worthy of further pre-clinical study. (C) 2017 Published by Elsevier Masson SAS.
• 6-Acylamino-2-aminoquinolines as Potent Melanin-Concentrating Hormone 1 Receptor Antagonists. Identification, Structure−Activity Relationship, and Investigation of Binding Mode
  作者：Trond Ulven、Thomas M. Frimurer、Jean-Marie Receveur、Paul Brian Little、Øystein Rist、Pia K. Nørregaard、Thomas Högberg

  DOI：10.1021/jm050103y

  日期：2005.9.1

  Novel 6-acylamino-2-aminoquinoline melanin-concentrating hormone 1 receptor (MCHIR) antagonists were identified by sequential in silico screening with 3D pharmacophore models derived from a series of benzamide antagonists. The structure- activity relationship exploration by synthesis of analogues found structural demands around the western part of the compounds to be quite specific, whereas much structural freedom was found in the eastern part. Vvhile these compounds in general suffered from poor solubility properties, the 4-trifluoromethoxy-phenoxyacetamide western appendage provided a favorable combination of activity and solubility properties. The amine in the eastern appendage, originally required by the pharmacophore model and believed to interact with Asp123 in transmembrane 3 of MCH1R, could be removed without diminishing affinity or functional activity of the compounds. Docking studies suggested that the Asp123 interacts preferentially with the nitrogen of the central quinoline. Synthesis and testing of specific analogues supported our revised binding mode hypothesis.